Valuation : Natera, Inc.

Market Cap 48.79B 41.87B 39.3B 35.9B 67.74B 4,653B 68.07B 465B 180B 2,347B 183B 179B 7,775B P/E 2026 *
-247x
P/E 2027 * -39,355x
Enterprise Value 47.72B 40.96B 38.44B 35.11B 66.26B 4,551B 66.58B 455B 176B 2,296B 179B 175B 7,605B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 13.6x
Free-Float
97.12%
Yield 2026 *
-
Yield 2027 * -
1 day+0.52%
1 week+4.12%
Current month+26.40%
1 month+29.18%
3 months+68.46%
6 months+56.62%
Current year+47.74%
1 week 320.41
Extreme 320.4101
340.96
1 month 248.03
Extreme 248.0275
340.96
Current year 181
Extreme 181
340.96
1 year 157.42
Extreme 157.425
340.96
3 years 36.9
Extreme 36.9
340.96
5 years 26.1
Extreme 26.1
340.96
10 years 7.35
Extreme 7.35
340.96
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Sell

Founder

-6,000 0.0042%
07/08/26 Sell

Founder

-2,000 0.0014%
07/08/26 Sell

Founder

-9,150 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%+4.12%+104.24%+489.84% 48.79B
-0.58%+1.60%+20.57%+58.22% 27.23B
+0.20%-14.69%-15.69%-37.60% 7.1B
-0.51%+1.23%+8.36%+138.22% 6.02B
-0.05%+2.80%+17.27%+77.43% 3.39B
+3.30%+13.35%-28.49%+2,024.35% 2.69B
+3.45%+4.29%+159.25%+24.78% 2.23B
+0.11%+2.08%+31.87%+24.40% 1.97B
-1.45%+1.24%-7.80%-51.91% 1.94B
-1.82%-4.93%+17.02%-10.36% 1.73B
Average +0.34%+1.95%+30.66%+273.74% 10.31B
Weighted average by Cap. +0.19%+2.08%+58.19%+307.93%

Financials

2026 *2027 *
Net sales 2.91B 2.49B 2.34B 2.14B 4.03B 277B 4.05B 27.7B 10.73B 140B 10.91B 10.67B 463B 3.48B 2.99B 2.8B 2.56B 4.83B 332B 4.86B 33.18B 12.86B 167B 13.07B 12.78B 555B
Net income -193M -166M -155M -142M -268M -18.4B -269M -1.84B -713M -9.28B -724M -709M -30.75B 9.13M 7.83M 7.35M 6.72M 12.68M 871M 12.74M 87.03M 33.73M 439M 34.27M 33.53M 1.45B
Net Debt -1.07B -917M -860M -786M -1.48B -102B -1.49B -10.18B -3.95B -51.4B -4.01B -3.92B -170B -1.36B -1.17B -1.1B -1B -1.89B -130B -1.9B -13B -5.04B -65.59B -5.12B -5.01B -217B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change
26/08/26 $338.45 +0.52%
25/08/26 $336.71 +2.74%
24/08/26 $327.72 -1.30%
21/08/26 $332.03 +2.21%
20/08/26 $324.84 -0.07%
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
338.45USD
Average target price
336.74USD
Spread / Average Target
-0.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock